Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays

International Journal of Laboratory Hematology

Volumn 38, Issue 5, 2016, Pages 505-513

  Gosselin, R ^a   Grant, R P ^b   Adcock, D M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LABORATORY CORPORATION OF AMERICA   (United States)

Author keywords

Anti Xa DOAC; anticoagulants; APTT; assays; coagulation; PT

Indexed keywords

ANTITHROMBIN; APIXABAN; BLOOD CLOTTING FACTOR 10A; DIMETHYL SULFOXIDE; EDOXABAN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; RIVAROXABAN; VIPER VENOM;

ARTICLE; BLOOD CLOTTING TEST; CONCENTRATION (PARAMETERS); DRUG EFFECT; HUMAN; LIQUID CHROMATOGRAPHY; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PLASMA; PRIORITY JOURNAL; PROTHROMBIN TIME; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; TANDEM MASS SPECTROMETRY;

EID: 84988359557     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/ijlh.12528     Document Type: Article

References (15)

1. Sindet-Pedersen C, Pallisgaard JL, Olesen JB,Gislason GH, Arevalo LC. Safety and efficacy of direct oral anticoagulants compared to warfarin for extended treatment of venous thromboembolism -a systematic review and meta-analysis. Thromb Res 2015;136:732–8.
2. Tahir F, Riaz H, Riaz T, Badshah MB, Riaz IB, Hamza A, Mohiuddin H. The new oral anticoagulants and the phase 3 clinical trials – a systematic review of the literature. Thromb J 2013;11:18.
3. Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Moia M, Palareti G, Poli D, Testa S, Tiraferri E, Tosetto A, Tripodi A, Siragusa S, Manotti C. Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. J Thromb Haemost 2012;10:1979–87.
4. Lippi G, Favaloro EJ. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus? Clin Chem Lab Med 2015;53:185–97.
5. Gosselin RC, Francart SJ, Hawes EM, Moll S, Dager WE, Adcock DM. Heparin-calibrated chromogenic anti-Xa activity measurements in patients receiving rivaroxaban: can this test be used to quantify drug level? Ann Pharmacother 2015;49:777–83.
6. Harenberg J, Marx S, Weiss C, Krämer R, Samama M, Schulman S; Subcommittee on Control of Anticoagulation of the ISTH. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban. J Thromb Haemost 2012;10:1433–6.
7. Harenberg J, Du S, Weiss C, Krämer R, Hoppensteadt D, Walenga J; Working party: methods to determine apixaban of the Subcommittee on Control of Anticoagulation of the International Society of Thrombosis and Haemostasis. Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH. J Thromb Haemost 2014;12:801–4.
8. Baglin T, Keeling D, Kitchen S; British Committee for Standards in Haematology. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br J Haematol 2012;159:427–9.
9. Gosselin RC, Adcock D, Hawes EM, Francart SJ, Grant RP, Moll S. Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban. Thromb Haemost 2015;113:77–84.
10. Kitchen S, Gray E, Mackie I, Baglin T, Baglin M; BCSH committee. Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis: guidance from the British Committee for Standards in Haematology. Br J Haematol 2014;166:830–41.
11. Benzon HT, Avram MJ, Green D, Bonow RO. New oral anticoagulants and regional anaesthesia. Br J Anaesth 2013;111(Suppl 1):i96–113.
12. Tran H, Joseph J, Young L, McRae S, Curnow J, Nandurkar H, Wood P, McLintock C. New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis. Intern Med J 2014;44:525–36.
13. Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E. Assessment of laboratory assays to measure rivaroxaban–an oral, direct factor Xa inhibitor. Thromb Haemost 2010;103:815–25.
14. College of American Pathologists. Proficiency Testing CGL, CGS4, and ACM Participant Summary. Northfield, IL: College of American Pathologists, 2015.
15. Gosselin RC, Francart SJ, Hawes EM, Moll S, Adcock-Funk D. Comparison of Anti-Xa and DRVVT assays in quantifying drug levels in patients taking therapeutic doses of rivaroxaban. Arch Pathol Lab Med 2014;138:1680–4.